Skip to main content
Top
Published in: Archives of Virology 2/2018

01-02-2018 | Original Article

Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C

Authors: Song Yang, Huichun Xing, Shenghu Feng, Wei Ju, Shunai Liu, Xiaomei Wang, Weini Ou, Jun Cheng, Calvin Q. Pan

Published in: Archives of Virology | Issue 2/2018

Login to get access

Abstract

There is little information on the association between baseline non-structural protein (NS) 5b resistance-associated variants (RAVs) and treatment failure in hepatitis C patients. This study examined the frequencies of natural hepatitis C virus (HCV) NS5B resistance-associated variants (RAVs) in an Asian cohort. Samples from Asian HCV patients enrolled between October 2009 and September 2014 were analyzed for NS5B RAVs within the region from amino acid 230 to 371. Serum samples were tested by PCR genotyping, with sequence alignment performed using the neighbor-joining method. NS5B was detected by Sanger sequencing followed by Geno2pheno analysis. NS5B RAVs were detected in 80.52% (1199/1489) of patients; 68.4% (1019/1489) and 79.7% (1186/1489) were associated with resistance to sofosbuvir (SOF) and dasabuvir (DSV), respectively. These RAVs were present in 95% (1004/1058) of genotype 1b patients. When genotypes 1b and 2a were compared, SOF-associated RAVs were detected at a higher frequency in genotype 1b (94.8% [1004/1058] vs. 2.9% [9/309]; χ2 = 1054.433, P < 0.001), C316H/N was more common in genotype 1b (94.7% [1002/1058] vs. 0% [0/309]; χ2 = 1096.014, P < 0.001), M289F/L/I/W/V had a higher frequency in genotype 2a (0.7% [7/309] vs. 2.3% [7/1058]; χ2 = 4.589, P = 0.032), DSV-associated RAVs were most often found in genotype 1b (95.0% [1005/1058] vs. 40.1% 124/309]; χ2 = 500.577, P < 0.001), and frequency of C316Y/H/N/W was higher in genotype 1b (94.7% [1002/1058] vs. 0% [0/309]; χ2 = 1096.014, P < 0.001). In conclusion, baseline SOF and DSV RAVs are common in Asian HCV patients and predominantly occur in genotype 1b.
Literature
1.
go back to reference AASLD/IDSA HCV Guidance Panel (2015) Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62:932–954CrossRef AASLD/IDSA HCV Guidance Panel (2015) Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62:932–954CrossRef
2.
go back to reference Chang CY, Nguyen P, Le A, Zhao C, Ahmed A, Daugherty T, Garcia G, Lutchman G, Kumari R, Nguyen MH (2017) Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine 96:e6128CrossRefPubMedPubMedCentral Chang CY, Nguyen P, Le A, Zhao C, Ahmed A, Daugherty T, Garcia G, Lutchman G, Kumari R, Nguyen MH (2017) Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine 96:e6128CrossRefPubMedPubMedCentral
3.
go back to reference Cho Y, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ (2015) Sofosbuvir-based therapy for patients with chronic hepatitis C: early experience of its efficacy and safety in Korea. Clin Mol Hepatol 21:358–364CrossRefPubMedPubMedCentral Cho Y, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ (2015) Sofosbuvir-based therapy for patients with chronic hepatitis C: early experience of its efficacy and safety in Korea. Clin Mol Hepatol 21:358–364CrossRefPubMedPubMedCentral
4.
go back to reference Donaldson EF, Harrington PR, O’Rear JJ, Naeger LK (2015) Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 61:56–65CrossRefPubMed Donaldson EF, Harrington PR, O’Rear JJ, Naeger LK (2015) Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 61:56–65CrossRefPubMed
5.
go back to reference Dong ZX, Zhou HJ, Wang JH, Xiang XG, Zhuang Y, Guo SM, Gui HL, Zhao GD, Tang WL, Wang H, Xie Q (2012) Distribution of hepatitis C virus genotypes in Chinese patients with chronic hepatitis C: correlation with patients’ characteristics and clinical parameters. J Dig Dis 13:564–570CrossRefPubMed Dong ZX, Zhou HJ, Wang JH, Xiang XG, Zhuang Y, Guo SM, Gui HL, Zhao GD, Tang WL, Wang H, Xie Q (2012) Distribution of hepatitis C virus genotypes in Chinese patients with chronic hepatitis C: correlation with patients’ characteristics and clinical parameters. J Dig Dis 13:564–570CrossRefPubMed
6.
go back to reference European Association for Study of Liver Diseases (2015) EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63:199–236CrossRef European Association for Study of Liver Diseases (2015) EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63:199–236CrossRef
7.
go back to reference Ju W, Yang S, Feng S, Wang Q, Liu S, Xing H, Xie W, Zhu L, Cheng J (2015) Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6. Virol J 12:109CrossRefPubMedPubMedCentral Ju W, Yang S, Feng S, Wang Q, Liu S, Xing H, Xie W, Zhu L, Cheng J (2015) Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6. Virol J 12:109CrossRefPubMedPubMedCentral
8.
go back to reference Kai Y, Hikita H, Morishita N, Murai K, Nakabori T, Iio S, Hagiwara H, Imai Y, Tamura S, Tsutsui S, Naito M, Nishiuchi M, Kondo Y, Kato T, Suemizu H, Yamada R, Oze T, Yakushijin T, Hiramatsu N, Sakamori R, Tatsumi T, Takehara T (2017) Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment. Sci Rep 7:41660CrossRefPubMedPubMedCentral Kai Y, Hikita H, Morishita N, Murai K, Nakabori T, Iio S, Hagiwara H, Imai Y, Tamura S, Tsutsui S, Naito M, Nishiuchi M, Kondo Y, Kato T, Suemizu H, Yamada R, Oze T, Yakushijin T, Hiramatsu N, Sakamori R, Tatsumi T, Takehara T (2017) Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment. Sci Rep 7:41660CrossRefPubMedPubMedCentral
9.
go back to reference Kalaghatgi P, Sikorski AM, Knops E, Rupp D, Sierra S, Heger E, Neumann-Fraune M, Beggel B, Walker A, Timm J, Walter H, Obermeier M, Kaiser R, Bartenschlager R, Lengauer T (2016) Geno2pheno[HCV]—a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents. PLoS One 11:e0155869CrossRefPubMedPubMedCentral Kalaghatgi P, Sikorski AM, Knops E, Rupp D, Sierra S, Heger E, Neumann-Fraune M, Beggel B, Walker A, Timm J, Walter H, Obermeier M, Kaiser R, Bartenschlager R, Lengauer T (2016) Geno2pheno[HCV]—a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents. PLoS One 11:e0155869CrossRefPubMedPubMedCentral
10.
go back to reference Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, Reisch T, Mondal R, Wagner R, Molla A, Maring C, Collins C (2015) In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 59:1505–1511CrossRefPubMedPubMedCentral Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, Reisch T, Mondal R, Wagner R, Molla A, Maring C, Collins C (2015) In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 59:1505–1511CrossRefPubMedPubMedCentral
11.
go back to reference Kieffer TL, George S (2014) Resistance to hepatitis C virus protease inhibitors. Curr Opin Virol 8:16–21CrossRefPubMed Kieffer TL, George S (2014) Resistance to hepatitis C virus protease inhibitors. Curr Opin Virol 8:16–21CrossRefPubMed
12.
go back to reference Kliemann DA, Tovo CV, da Veiga AB, de Mattos AA, Wood C (2016) Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World J Gastroenterol 22:8910–8917CrossRefPubMedPubMedCentral Kliemann DA, Tovo CV, da Veiga AB, de Mattos AA, Wood C (2016) Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World J Gastroenterol 22:8910–8917CrossRefPubMedPubMedCentral
13.
go back to reference Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, Keilman M, Zhu Y, Lan S, Otto MJ, Furman PA (2012) Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56:3359–3368CrossRefPubMedPubMedCentral Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, Keilman M, Zhu Y, Lan S, Otto MJ, Furman PA (2012) Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56:3359–3368CrossRefPubMedPubMedCentral
14.
go back to reference Marascio N, Pavia G, Strazzulla A, Dierckx T, Cuypers L, Vrancken B, Barreca GS, Mirante T, Malanga D, Oliveira DM, Vandamme AM, Torti C, Liberto MC, Foca A, The Sinergie-Umg Study G (2016) Detection of natural resistance-associated substitutions by ion semiconductor technology in HCV1b positive, direct-acting antiviral agents-naive patients. Int J Mol Sci 17:1416CrossRefPubMedCentral Marascio N, Pavia G, Strazzulla A, Dierckx T, Cuypers L, Vrancken B, Barreca GS, Mirante T, Malanga D, Oliveira DM, Vandamme AM, Torti C, Liberto MC, Foca A, The Sinergie-Umg Study G (2016) Detection of natural resistance-associated substitutions by ion semiconductor technology in HCV1b positive, direct-acting antiviral agents-naive patients. Int J Mol Sci 17:1416CrossRefPubMedCentral
15.
go back to reference Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, Bruno R, Baldanti F (2013) Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol J 10:355CrossRefPubMedPubMedCentral Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, Bruno R, Baldanti F (2013) Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol J 10:355CrossRefPubMedPubMedCentral
16.
go back to reference Patino-Galindo JA, Salvatierra K, Gonzalez-Candelas F, Lopez-Labrador FX (2016) Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6. Antimicrob Agents Chemother 60:2402–2416CrossRefPubMedPubMedCentral Patino-Galindo JA, Salvatierra K, Gonzalez-Candelas F, Lopez-Labrador FX (2016) Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6. Antimicrob Agents Chemother 60:2402–2416CrossRefPubMedPubMedCentral
18.
go back to reference Sarrazin C (2016) The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 64:486–504CrossRefPubMed Sarrazin C (2016) The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 64:486–504CrossRefPubMed
19.
go back to reference Shepherd SJ, Abdelrahman T, MacLean AR, Thomson EC, Aitken C, Gunson RN (2015) Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. J Clin Virol 65:50–53CrossRefPubMedPubMedCentral Shepherd SJ, Abdelrahman T, MacLean AR, Thomson EC, Aitken C, Gunson RN (2015) Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. J Clin Virol 65:50–53CrossRefPubMedPubMedCentral
20.
go back to reference Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, Konno J, Kimura M, Kawagishi N, Ohara M, Umemura M, Ito J, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Tsubota A, Shimada N, Iio E, Tanaka Y, Sakamoto N (2017) Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. J Gastroenterol. https://doi.org/10.1007/s00535-017-1328-z (Epub ahead of print) Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, Konno J, Kimura M, Kawagishi N, Ohara M, Umemura M, Ito J, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Tsubota A, Shimada N, Iio E, Tanaka Y, Sakamoto N (2017) Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. J Gastroenterol. https://​doi.​org/​10.​1007/​s00535-017-1328-z (Epub ahead of print)
21.
go back to reference Svarovskaia ES, Gane E, Dvory-Sobol H, Martin R, Doehle B, Hedskog C, Jacobson IM, Nelson DR, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H (2016) L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis 213:1240–1247CrossRefPubMed Svarovskaia ES, Gane E, Dvory-Sobol H, Martin R, Doehle B, Hedskog C, Jacobson IM, Nelson DR, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H (2016) L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis 213:1240–1247CrossRefPubMed
22.
go back to reference Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, Yan JM, So SS, Klumpp K, Najera I (2014) In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis 209:668–675CrossRefPubMed Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, Yan JM, So SS, Klumpp K, Najera I (2014) In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis 209:668–675CrossRefPubMed
23.
go back to reference Uchida Y, Kouyama JI, Naiki K, Sugawara K, Inao M, Imai Y, Nakayama N, Mochida S (2016) Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism. Hepatol Res 46:1234–1246CrossRefPubMed Uchida Y, Kouyama JI, Naiki K, Sugawara K, Inao M, Imai Y, Nakayama N, Mochida S (2016) Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism. Hepatol Res 46:1234–1246CrossRefPubMed
24.
go back to reference Xu S, Doehle B, Rajyaguru S, Han B, Barauskas O, Feng J, Perry J, Dvory-Sobol H, Svarovskaia ES, Miller MD, Mo H (2017) In vitro selection of resistance to sofosbuvir in HCV replicons of genotype 1 to 6. Antivir Ther. https://doi.org/10.3851/IMP3149 (Epub ahead of print) Xu S, Doehle B, Rajyaguru S, Han B, Barauskas O, Feng J, Perry J, Dvory-Sobol H, Svarovskaia ES, Miller MD, Mo H (2017) In vitro selection of resistance to sofosbuvir in HCV replicons of genotype 1 to 6. Antivir Ther. https://​doi.​org/​10.​3851/​IMP3149 (Epub ahead of print)
Metadata
Title
Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C
Authors
Song Yang
Huichun Xing
Shenghu Feng
Wei Ju
Shunai Liu
Xiaomei Wang
Weini Ou
Jun Cheng
Calvin Q. Pan
Publication date
01-02-2018
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 2/2018
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-017-3640-6

Other articles of this Issue 2/2018

Archives of Virology 2/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.